Catheter Precision

Catheter Precision ROCE

The Return on Capital Employed (ROCE) of Catheter Precision (VTAK) as of Oct 22, 2026 is -289.04 %. In the previous year, Return on Capital Employed (ROCE) was -114.07 % — a change of 153.39% (lower).

ROCE

-289.04 %

YoY

153.39%

Last updated:

In 2025, Catheter Precision's return on capital employed (ROCE) was -289.04 %, a 153.39% increase from the -114.07 % ROCE in the previous year.

The Catheter Precision ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-46.71 USD
Jan 1, 2019
-174.15 USD
Jan 1, 2020
-170.52 USD
Jan 1, 2021
-214.04 USD
Jan 1, 2022
-291.16 USD
Jan 1, 2023
-368.61 USD
Jan 1, 2024
-114.07 USD
Jan 1, 2025
-289.04 USD
The Catheter Precision ROCE history
YEARROCEYoY
-289.04 %+153.39%
-114.07 %-69.05%
-368.61 %+26.60%
-291.16 %+36.03%
-214.04 %+25.53%
-170.52 %-2.09%
-174.15 %+272.80%
-46.71 %-120.03%
233.22 %-78.89%
1,104.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Catheter Precision Stock analysis

What does Catheter Precision do? Ra Medical Systems, Inc. generates revenue through the sale of its electrophysiology products Amigo, VIVO, and LockeT to hospitals, physicians, and healthcare providers. The company's Amigo remote catheter system, featuring an open architecture design, allows for versatile use across multiple catheter procedures. VIVO, a non-invasive 3D imaging system, helps physicians identify arrhythmia origins pre-procedure, improving workflow efficiency. LockeT, a suture retention device, supports surgical procedures. These products target cardiac arrhythmia treatment, serving medical institutions and healthcare professionals seeking advanced solutions for patient care. The firm collaborates with physicians to develop and advance its electrophysiology technologies, focusing on improving cardiac arrhythmia procedures. Its product portfolio addresses the need for streamlined workflows and reduced procedure times in electrophysiology settings. Hospitals and physicians purchase these solutions to enhance patient outcomes and operational efficiency in treating vascular immune-mediated inflammatory diseases. The company's commercialization strategy centers on delivering innovative technologies that meet evolving clinical demands in cardiology. Ra Medical Systems, Inc. is engaged in providing new solutions to the market for cardiac arrhythmia treatment, emphasizing technology development for electrophysiology procedures. Its products are designed to improve patient lives through advanced catheter-based systems and imaging solutions. The company's focus on physician collaboration ensures that its offerings align with clinical needs, driving adoption among healthcare providers specializing in cardiac care. Catheter Precision is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Catheter Precision's Return on Capital Employed (ROCE)

Catheter Precision's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Catheter Precision's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Catheter Precision's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Catheter Precision’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Catheter Precision stock

Return on Capital Employed (ROCE) of Catheter Precision is -289.04 % in 2025.

Return on Capital Employed (ROCE) of Catheter Precision changed from -114.07 % to -289.04 %, representing a 153.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Catheter Precision since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Catheter Precision with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Catheter Precision

All Key Metrics — Catheter Precision